That's odd. This was content that was still on the MCAT when I took it last year. I even remember keeping the formation of objection permanence occuring ~0-2 years of age on my flashcards.
You're mostly correct but immunotherapies do work for a many different type of cancer. The issue is differences in tumor biology plays a major factor. The even bigger caveat is that given a sufficient amount of tumor…
I believe he got just got either Ipilimumab and Nivolumab as a combo therapy or Pembrolizumab. He's a researcher who focuses on neo-adjuvant (use therapy before resection) therapy in melanomas. It was a good gamble to…
It's neo-adjuvant (treat prior to surgery) with a three mAbs: Ipi + Nivo, which is a well established combo of immunotherapeutics for many solid tumors, rounded out with relatlimab which I'm less familiar with (LAG-3…
Ok very quick notes • Prostate cancers are known to have a wide spectrum of outcomes. • Stage IV (metastatic) disease tends to have genetic testing. These panels tend to be on the order of a few hundred genes to 1000s…
Personally, I think confabulations would be a better term. To the best of my understanding, these AI rely on a model similar to the reconstructive theory of memory in humans. The connotation of the word confabulation…
This theory probably has more transnational value to oncology in the nearer term than anti-aging IMO.
Actual article here: https://www.embopress.org/doi/abs/10.15252/embj.2022111133 Edit: My best read of the article is as follow, please correct me if I am wrong. RB is retinoblastoma gene which is a well known tumor…
TBH I'm surprised how hard Illumina is already pushing Galleri as a product. Current ctDNA/cfDNA are imperfect for advanced cancers which should have a lot of shedding to begin with. Additionally CHIP is and outstanding…
That's odd. This was content that was still on the MCAT when I took it last year. I even remember keeping the formation of objection permanence occuring ~0-2 years of age on my flashcards.
You're mostly correct but immunotherapies do work for a many different type of cancer. The issue is differences in tumor biology plays a major factor. The even bigger caveat is that given a sufficient amount of tumor…
I believe he got just got either Ipilimumab and Nivolumab as a combo therapy or Pembrolizumab. He's a researcher who focuses on neo-adjuvant (use therapy before resection) therapy in melanomas. It was a good gamble to…
It's neo-adjuvant (treat prior to surgery) with a three mAbs: Ipi + Nivo, which is a well established combo of immunotherapeutics for many solid tumors, rounded out with relatlimab which I'm less familiar with (LAG-3…
Ok very quick notes • Prostate cancers are known to have a wide spectrum of outcomes. • Stage IV (metastatic) disease tends to have genetic testing. These panels tend to be on the order of a few hundred genes to 1000s…
Personally, I think confabulations would be a better term. To the best of my understanding, these AI rely on a model similar to the reconstructive theory of memory in humans. The connotation of the word confabulation…
This theory probably has more transnational value to oncology in the nearer term than anti-aging IMO.
Actual article here: https://www.embopress.org/doi/abs/10.15252/embj.2022111133 Edit: My best read of the article is as follow, please correct me if I am wrong. RB is retinoblastoma gene which is a well known tumor…
TBH I'm surprised how hard Illumina is already pushing Galleri as a product. Current ctDNA/cfDNA are imperfect for advanced cancers which should have a lot of shedding to begin with. Additionally CHIP is and outstanding…